SBA Member, 07.06.2017
US approval of Xadago in Parkinson’s disease triggered a total of EUR 11.3 mn milestone payments from Zambon. More than 60 sales representative will initially support US launch by US WorldMeds in July. Evenamide now contributes to our forecasts due to positive proof-of-concept results in schizophrenia. Newron is evaluating a EUR 25 mn fund raise for a potentially pivotal phase IIb/III trial of evenamide in schizophrenia to maximize its long-term value. Newron has a cash runway into 2019 with cash of CHF 51 mn (December 31st, 2016). Sarizotan in Rett syndrome has the potential to become Newron’s second drug on the market after Xadago, however, with far higher profit margins.
Key catalysts include:
• Xadago US launch (July 2017)
• Next steps to maximize value of evenamide (H2 2017)
• Top line results sarizotan “STARS” trial in Rett syndrome (mid 2018)
M: +41 79 652 6768